MarketCap
Facebook
X
TelegramAnnual report 2024
added 01-17-2026
Aptorum Group Limited EV/EBITDA Ratio 2011-2026 | APM
Annual EV/EBITDA Ratio Aptorum Group Limited
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 29.4 | -4.82 | -25.6 | -41 | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 29.4 | -41 | -10.5 |
EV/EBITDA Ratio of other stocks in the Biotechnology industry
| Issuer | EV/EBITDA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biogen
BIIB
|
12.7 | $ 173.17 | 0.92 % | $ 25.2 B |  USA |
 |
MorphoSys AG
MOR
|
-0.591 | - | 2.43 % | $ 254 M |  Germany |
 |
Adagene
ADAG
|
-4.92 | $ 2.4 | -3.61 % | $ 135 M |  China |
 |
Acorda Therapeutics
ACOR
|
0.777 | - | -24.86 % | $ 820 K | USA |
 |
BioNTech SE
BNTX
|
4.1 | $ 117.62 | 1.41 % | $ 27.2 B | Germany |
 |
Alterity Therapeutics Limited
ATHE
|
-0.994 | $ 3.67 | 3.38 % | $ 8.83 B |  Australia |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
10.7 | - | - | $ 40.3 B | USA |
 |
Catalyst Biosciences
CBIO
|
0.34 | $ 11.66 | -8.95 % | $ 768 M | USA |
 |
Biophytis SA
BPTS
|
-17.6 | - | -13.47 % | $ 169 M |  France |
 |
Midatech Pharma plc
MTP
|
0.796 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-3.42 | - | -1.52 % | $ 24.7 M | USA |
 |
Akero Therapeutics
AKRO
|
-4.64 | - | - | $ 3.67 B | USA |
 |
BioXcel Therapeutics
BTAI
|
-2.43 | $ 1.77 | -2.75 % | $ 4.49 M | USA |
 |
BioLineRx Ltd.
BLRX
|
-53.5 | $ 3.12 | 0.59 % | $ 908 M |  Israel |
 |
Applied Molecular Transport
AMTI
|
-1.19 | - | - | $ 10.1 M | USA |
 |
Cellectis S.A.
CLLS
|
-1.37 | $ 4.13 | -6.56 % | $ 116 M | France |
 |
Институт стволовых клеток человека
ISKJ
|
14 | - | - | - |  Russia |
 |
Ascendis Pharma A/S
ASND
|
-15.7 | $ 233.49 | -0.81 % | $ 5 B |  Danmark |
 |
ARCA biopharma
ABIO
|
1.84 | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
1.8 | - | 4.01 % | $ 150 M |  Canada |
 |
Arrowhead Pharmaceuticals
ARWR
|
-30.8 | $ 67.41 | 0.54 % | $ 9.02 B | USA |
 |
Compugen Ltd.
CGEN
|
-7.07 | $ 2.04 | -2.39 % | $ 183 M | Israel |
 |
Can-Fite BioPharma Ltd.
CANF
|
-43.1 | $ 4.36 | -2.46 % | $ 9.49 B | Israel |
 |
Aeterna Zentaris
AEZS
|
4.4 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-1.85 | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-4.27 | - | - | $ 1.01 B | USA |
 |
Akouos
AKUS
|
-1.13 | - | 0.23 % | $ 488 M | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
-12.7 | - | -15.15 % | $ 60.3 M | Britain |
 |
Amphastar Pharmaceuticals
AMPH
|
17.3 | $ 26.57 | 2.51 % | $ 1.29 B | USA |
 |
Coherus BioSciences
CHRS
|
-4.11 | $ 2.26 | 9.7 % | $ 213 M | USA |
 |
Amneal Pharmaceuticals
AMRX
|
1.63 | $ 13.59 | 1.46 % | $ 4.2 B | USA |
 |
AIkido Pharma
AIKI
|
-45.5 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-3.38 | - | -0.23 % | $ 916 M | USA |
 |
CureVac N.V.
CVAC
|
-7.74 | - | - | $ 867 M | Germany |
 |
Aptose Biosciences
APTO
|
388 | - | -45.71 % | $ 1.2 M | Canada |
 |
Acer Therapeutics
ACER
|
-3.39 | - | 2.71 % | $ 14 M | USA |
 |
Aravive
ARAV
|
-0.158 | - | -13.39 % | $ 1.45 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-5.5 | - | - | $ 2.17 B | USA |
 |
AlloVir
ALVR
|
-3.61 | - | 4.14 % | $ 49.1 M | USA |
 |
Athira Pharma
ATHA
|
-3.66 | - | - | $ 269 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-20.4 | - | -11.43 % | $ 502 K | USA |
 |
Celldex Therapeutics
CLDX
|
0.185 | $ 26.72 | 3.09 % | $ 1.72 M | USA |
 |
AVROBIO
AVRO
|
0.957 | - | 1083.1 % | $ 745 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
0.785 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-1.92 | $ 2.75 | 1.85 % | $ 17.3 M | USA |
 |
AstraZeneca PLC
AZN
|
76.5 | $ 94.24 | 1.38 % | $ 96.9 B | Britain |
 |
Arena Pharmaceuticals
ARNA
|
-9.01 | - | -6.81 % | $ 3.04 B | USA |
 |
Brickell Biotech
BBI
|
0.668 | - | -5.38 % | $ 6.06 M | USA |